Understanding toxicity in prostate cancer treatment
Radiation Induced Toxicity in Prostate Cancer
This study looks at how treatment for prostate cancer affects patients' side effects and quality of life over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University Medical Center Groningen Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Groningen) |
| Trial ID | NCT03034187 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather insights into the development and progression of toxicity experienced by patients after curative treatment for prostate cancer. Participants will be enrolled in a Standard Follow-up Programme (SFP) and will complete weekly questionnaires to assess patient-rated toxicity. Additionally, biweekly evaluations by radiation oncologists will provide physician-rated toxicity scores. The study focuses on both acute and late toxicity, as well as the impact on quality of life for these patients.
Who should consider this trial
Good fit: Ideal candidates include prostate cancer patients who have undergone curative treatment, including those with positive lymph nodes.
Not a fit: Patients who are not receiving curative treatment or those with non-prostate cancers will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the management of toxicity in prostate cancer patients, leading to improved quality of life.
How similar studies have performed: While there have been studies on toxicity in cancer treatments, this specific approach focusing on a structured follow-up program is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All curative treated patients with prostatecancer( with positive lymph nodes) * All patients who will be treated with RT( including post-operative, adjuvant treatments) * Are willing to fill in toxicity and QOL-questionnarys (QLQ-PR25 en de QLQ-C30) Exclusion Criteria: Patients who are not willing to fill in toxicity and QOL-questionnarys Patients who will not get RT Non-curative or palliative treated patients (with bone mestasis) Non-prostate cancer-patients
Where this trial is running
Groningen
- University Medical Center Groningen — Groningen, Netherlands (Recruiting)
Study contacts
- Study coordinator: S. Aluwini, MD PhD
- Email: s.al-uwini@umcg.nl
- Phone: +31503612346
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.